araag2/HINT huggingface dataset:
Clinical trial NCT00314951 (phase 3, status: completed)
Conditions: clostridium infections, diarrhea
ICD codes: A05.2, A04.71, A04.72, B96.7, K59.1, R19.7, P78.3, K58.0, K58.9
Drugs: fidaxomicin, vancomycin, matching placebo to fidaxomicin
SMILES: CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\C(=O)OC(C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males/females with CDAD

          -  Females must use adequate contraception

          -  Signed informed consent

        Exclusion Criteria:

          -  Life-threatening CDAD

          -  Toxic megacolon

          -  Pregnant

          -  Concurrent use of diarrheal agents

          -  Participation in other trials
Clinical trial NCT00003118 (phase 3, status: completed)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: cisplatin, fluorouracil
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        1. Patients with histologically documented untreated squamous cell carcinoma or
             adenocarcinoma of the thoracic esophagus (below 20 cm) or gastro-esophageal junction
             and with less than 2 cm distal spread into the gastric cardia were eligible.

          2. No evidence of distant metastatic disease by history and physical examination

          3. Upper endoscopy with biopsy, computed tomography (CT) of the chest and upper abdomen,
             and pulmonary function studies are required.

          4. Bone scan is required for alkaline phosphatase more than 3X the institutional normal
             value.

          5. Bronchoscopy is required if the primary tumor was adjacent to the trachea or left main
             stem bronchus.

          6. Patients are required to have:

               -  granulocyte counts ≥1,800/mL

               -  platelet count ≥ 100,000/mL

               -  creatinine clearance ≥ 50 mL/min

          7. Esophageal ultrasound (EUS) and preresection staging by thoracoscopy (ts) and
             laparoscopy/minilaparotomy (ls), including biopsy of celiac axis and lesser curvature
             are recommended

          8. Tumors must be considered surgically resectable (T1-3, NX), including regional
             thoracic lymph node (N1) metastases.

          9. Patients with supraclavicular lymph nodes measuring ≤ 1.5 cm by CT (not palpable) are
             eligible.

         10. Patients with lymph node metastases to levels 15 to 20 (predominantly celiac axis and
             paracardial nodes) ≤1.5 cm by CT.

         11. Patients may not have previously received chemotherapy or radiation therapy for this
             tumor or any radiation therapy that would overlap the radiation fields required for
             this malignancy.

         12. Patients with previous malignancies are eligible if more than 5 years had elapsed from
             diagnosis without evidence of tumor recurrence.

         13. There can be no other serious illness that would limit survival to less than 2 years,
             or psychiatric condition that would prevent compliance with treatment or informed
             consent. Patients with uncontrolled or severe cardio- vascular disease,pulmonary
             disease, oractive infections are excluded.

         14. Pregnant patients are excluded.

         15. Informed consent is required for all patients.
Clinical trial NCT01114217 (phase 3, status: completed)
Conditions: iron deficiency anemia
ICD codes: D50.9, D50.0, D50.8
Drugs: ferumoxytol
SMILES: COC1=CC=CC=C1OCC(O)CO
Eligibility criteria:

        Key Inclusion Criteria include:

          1. Participants who completed participation in study AMAG-FER-IDA-301 [NCT01114139]

          2. Female participants of childbearing potential who are sexually active must be on an
             effective method of birth control and agree to remain on birth control until
             completion of participation in the study

        Key Exclusion Criteria include:

          1. Experienced a serious adverse event (SAE) related to ferumoxytol in study
             AMAG-FER-IDA-301

          2. Female participants who are pregnant, intend to become pregnant, are breastfeeding, or
             have a positive serum/urine pregnancy test
Clinical trial NCT01071161 (phase 3, status: completed)
Conditions: cough, chronic obstructive pulmonary disease, chronic bronchitis
ICD codes: R05.1, R05.2, R05.3, R05.4, R05.9, G44.83, J45.991, J44.9, J44.1, J44.0, J41.0, J41.1, J42, J41.8, J40
Drugs: azithromycin, placebo
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients > 40 years of age, in our outpatient clinic with chronic cough and COPD
             (gold2-4)

          -  Chronic cough is defined as a cough > 12 weeks duration, at least 12 weeks a year in 2
             subsequent years.

          -  Analysed for bronchiectasis prior to participation by CT-thorax.

        Exclusion Criteria:

          -  Prior history of asthma

          -  Use of i.v. or oral corticosteroids and or antibiotics for an exacerbation 3 weeks
             before inclusion

          -  Patients suffering from other relevant lung diseases.

          -  Clinically relevant abnormal laboratory values suggesting an unknown disease requiring
             further clinical evaluation.

          -  Liver disease, (ALAT and/or ASAT levels two or more times the upper limit of normal).

          -  Pregnancy or lactation.

          -  Use of macrolides the last 6 weeks prior to inclusion.

          -  Allergy or intolerance to macrolides.

          -  Other research medication started 2 months prior to inclusion.

          -  Prior randomisation in this study.
Clinical trial NCT00478023 (phase 3, status: completed)
Conditions: hysterectomy, postoperative
ICD codes: N99.3
Drugs: morphine, cg5503 ir, cg5503 ir, cg5503 ir, placebo
SMILES: CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female between 18 and 80 years of age;

          -  Scheduled to undergo an abdominal hysterectomy with or without bilateral
             salpingo-oophorectomy due to uterine leiomyomas, or dysfunctional uterine bleeding or
             endometrial hyperplasia;

          -  Anesthesiological and surgical procedures performed according to protocol;

          -  Moderate or severe baseline pain following hysterectomy on a Verbal Rating Scale (VRS)
             within 6 hours following the last possible application of morphine subcutaneous;

          -  Pain following hysterectomy of at least 4 on an 11-point Numeric Rating Scale (NRS)
             within 6 hours following the last possible application of morphine subcutaneous;

          -  American Society of Anesthesiologists (ASA) classification I-III.

        Exclusion Criteria:

          -  Vaginal hysterectomy;

          -  Ongoing or known history of painful endometriosis;

          -  Known or suspected chronic pelvic pain syndrome;

          -  Previous abdominal or pelvic open surgery;

          -  History of seizure disorder or epilepsy;

          -  History of alcohol or drug abuse;

          -  Evidence of active infections that may spread to other areas of the body;

          -  severely impaired renal function, moderately or severely impaired hepatic function,

          -  Allergy or hypersensitivity to oxycodone, morphine, fentanyl hydromorphone, heparin,
             or any compound planned to be used during the anesthesia;

          -  Serious complication during surgery and up to randomization;

          -  Pre-operative use within 12hours prior to surgery or peri-operative use of
             non-steroidal anti-inflammatory drugs (NSAIDs);

          -  Treated regularly with opioid analgesic or non-steroidal anti-inflammatory drugs
             (NSAIDs) within 30 days prior to screening;
Clinical trial NCT00662909 (phase 3, status: completed)
Conditions: urinary bladder, overactive
ICD codes: N32.81
Drugs: mirabegron, placebo
SMILES: NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is willing and able to complete the micturition diary and questionnaires
             correctly

          -  Patient has symptoms of overactive bladder for ≥ 3 months

          -  Patient must experience frequency of micturition on average ≥ 8 times per 24-hour
             period during the 3-day micturition diary period

          -  Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without
             incontinence during the 3-day micturition diary period

        Exclusion Criteria:

          -  Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of
             childbearing potential, sexually active and not practicing a highly reliable method of
             birth control

          -  Patient has significant stress incontinence or mixed stress/urge incontinence where
             stress is the predominant factor

          -  Patient has an indwelling catheter or practices intermittent self-catheterization

          -  Patient has diabetic neuropathy

          -  Patient has evidence of a symptomatic urinary tract infection, chronic inflammation
             such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or
             previous or current malignant disease of the pelvic organs

          -  Patient receives non-drug treatment including electro-stimulation therapy

          -  Patient has severe hypertension

          -  Patient has a known or suspected hypersensitivity to YM178, other beta-adrenoreceptor
             (ß-AR) agonists, or any of the other inactive ingredients

          -  Patient has been treated with any investigational drug or device within 30 days

          -  Patient had an average total daily urine volume > 3000 mL as recorded in the 3-day
             micturition diary period

          -  Patient has serum creatinine of >150 μmol/L, or aspartate aminotransferase (AST) or
             alanine aminotransferase (ALT) > 2x upper limit of normal range (ULN), or Gamma
             glutamyl transferase (γ-GT) > 3x ULN

          -  Patient has a clinically significant abnormal electrocardiogram (ECG)
Clinical trial NCT00442546 (phase 3, status: completed)
Conditions: osteoarthritis, postoperative pain
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: pregabalin, pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with osteoarthritis (OA) undergoing elective TKA under regional anesthesia
             (neuroaxial with or without peripheral nerve block).

          -  Subjects able to demonstrate sufficient psychomotor dexterity and cognitive capacity
             to use Patient Controlled Analgesia/Patient Controlled Epidural Analgesia if used as
             part of the standard of care.

          -  The subject's preoperative health is graded as American Society of Anesthesiology
             Class 1 to Class 3

        Exclusion Criteria:

          -  Subjects undergoing revision, unicompartmental, bilateral total knee arthroplasty or
             subjects with planned second knee total knee arthroplasty at time of present
             procedure.

          -  Subjects with inflammatory arthritides (i.e., rheumatoid arthritis, lupus, ankylosing
             spondylitis, psoriatic arthritis); Lyme disease.

          -  Subjects with fibromyalgia and or other chronic pain syndromes
Clinical trial NCT00206440 (phase 3, status: terminated)
Conditions: nausea
ICD codes: R11.0, R11.11, R11.2
Drugs: esomeprazole
SMILES: COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Reason stopped: 
    accrual was not optimized
  
Eligibility criteria:

        Inclusion Criteria:

        For inclusion, participants must:

          -  be female, age 18 years or older

          -  sign an informed consent

          -  have Stage I, II, or III breast cancer

          -  be receiving at least four cycles of anthracycline-based chemotherapy which may
             include: doxorubicin/cyclophosphamide AC),5-fluorouracil/doxorubicin/cyclophosphamide
             (FAC), fluoruracil/epirubicin/cyclophosphamide (FEC) or dose dense chemotherapy
             regimen (AC every two weeks) as their agents for neoadjuvant or adjuvant chemotherapy

          -  patient must receive a serotonin receptor antagonist and a steroid for premedication

          -  have a negative serum pregnancy test within 7 days prior to starting study if
             pre-menopausal

          -  have adequate renal function, defined by a serum creatinine within 1.5 times the upper
             limit of normal

          -  have adequate liver function, defined by a total bilirubin, SGOT, alkaline phosphatase
             and albumin within 1.5 times the upper limits of normal

          -  have adequate bone marrow function, defined as a WBC >4.0, platelet count >100K, and
             HCT >30

          -  have no prior or current malignancies for which chemotherapy was utilized

          -  have a performance status of at least 2 according to the Eastern Cooperative Oncology
             Group World Health Organization or a Karnofsky score of 50% or greater.

        Exclusion Criteria:

          -  pregnancy or unwillingness to use a reliable contraceptive method in women of
             child-bearing potential

          -  severe or underlying chronic illness or disease

          -  renal insufficiency or liver abnormalities

          -  chronic use of steroids

          -  uncontrolled GERD

          -  current use of proton pump inhibitors

          -  history of Barrett's esophagus

          -  history of erosive gastritis

          -  intolerance to serotonin receptor antagonists

          -  current use of aprepitant or palonosetron as antiemetics

          -  concomitant use of H2-receptor antagonists (ranitidine, cimetidine, famotidine or
             nizatidine) or metaclopramide
Clinical trial NCT01641640 (phase 3, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: sofosbuvir, rbv, peg
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Infection with HCV genotype 1, 4, 5, or 6

          -  Cirrhosis determination

          -  Subject met the following classifications:

               -  Treatment-naive

               -  Screening laboratory values within defined thresholds

               -  Not treated with any investigational drug or device within 30 days of screening

          -  Use of highly effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein
             (NS)5B polymerase

          -  Pregnant or nursing female, or male with pregnant female partner

          -  Current or prior history of clinical hepatic decompensation

          -  History of clinically-significant illness or any other major medical disorder that may
             have interfered with subject treatment, assessment, or compliance with the protocol

          -  Excessive alcohol ingestion or significant drug abuse
Clinical trial NCT01392677 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus, high hba1c level, inadequate glycaemic control
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, Z59.1, O62.0, Z72.821, Z58.6, Z62.0, Z73.4
Drugs: dapagliflozin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Men or women age ≥ 18 years old

          -  Stable dose combination of metformin and sulfonylurea

          -  HbA1c ≥7.7% and ≤11.0%

        Exclusion Criteria:

          -  Type 1 diabetes mellitus or diabetes insipidus

          -  Recent cardiovascular events

          -  Kidney or urological disorders

          -  Hepatic disorders
Clinical trial NCT00503698 (phase 3, status: terminated)
Conditions: chronic kidney disease, end-stage renal disease
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, N18.6, I12.0, I13.11, I13.2
Drugs: somatropin, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    see termination reason in detailed description
  
Eligibility criteria:

        Inclusion Criteria:

          -  Serum albumin as specified in protocol

          -  Malnourished (based on serum albumin value below 40 g/L, assessed centrally)

          -  Stable (for 3 months or more) and adequate haemodialysis treatment three months prior
             to enrolment as defined by Kt/V of more than 1.2

        Exclusion Criteria:

          -  Active malignant disease

          -  Critical illness requiring treatment in an intensive care unit (ICU)

          -  Uncontrolled treated/untreated hypertension

          -  Patients on chronic (more than 3 months) treatment with steroids in doses of more than
             10 mg/day prednisolone (or equivalent)

          -  Patients treated with immunosuppressive agents

          -  Known Growth Hormone Deficiency

          -  Patients suffering from any clinically significant disease history in the opinion of
             the investigator

          -  Severe illness as defined in the protocol (as judged by the investigator)
Clinical trial NCT01191268 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin glargine, ly2189265, insulin lispro
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Currently using insulin for at least 3 months with a conventional insulin regimen with
             or without oral medications

          -  Glycosylated hemoglobin (HbA1c) greater than or equal to 7% and less than or equal to
             11%

          -  Willing to inject subcutaneous medication

          -  Willing to monitor blood glucose levels and adjust insulin dose

          -  Willing to maintain a study diary

          -  Body mass index (BMI) between 23 and 45 kilograms per square meter (kg/m^2)

          -  Stable weight for 3 months prior to screening

          -  Females of child bearing potential must test negative for pregnancy at screening and
             be willing to use a reliable method of birth control during the study and for 1 month
             following the last dose of study drug

        Exclusion Criteria:

          -  Type 1 Diabetes

          -  Previous therapy with glucagon-like peptide 1 (GLP-1) agonists within 3 months prior
             to screening

          -  1 or more episodes of ketoacidosis within 6 months prior to screening

          -  Have been treated with prescription or over the counter medication to promote weight
             loss within 3 months prior to screening

          -  Estimated glomerular filtration rate (eGFR) less than or equal to 30 milliliters per
             minute per 1.73 square meters (mL/min/1.73 m^2) at screening

          -  Taking steroids for greater than 14 days except for topical, eye, nasal, or inhaled

          -  History of heart failure, New York Heart Classification III or IV within 2 months
             prior to screening

          -  Gastrointestinal (GI) problems such as diabetic gastroparesis or bariatric surgery
             (stomach stapling) or chronically taking medications that directly affect GI motility

          -  Acute or chronic hepatitis or pancreatitis

          -  Self or family history of 2A or type 2B multiple endocrine neoplasia or medullary
             C-Cell hyperplasia

          -  Serum calcitonin greater than or equal to 20 picograms per milliliter (pcg/mL) at
             screening

          -  Organ transplant except cornea

          -  Significant active autoimmune disease such as Lupus or Rheumatoid Arthritis

          -  History of or active malignancy except skin or in situ cervical or prostate cancer
             within the last 5 years

          -  Known drug or alcohol abuse

          -  Have enrolled in another clinical trial within the last 30 days

          -  Have previously signed an informed consent or participated in a LY2189265 study
Clinical trial NCT00494884 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Male, non-fertile female or female of childbearing potential using a medically
             approved birth control method

          -  Patients who have received metformin for at least three months prior to visit 1 and
             have been on a stable dose for a minimum of 8 weeks prior to visit 1

          -  Agreement to maintain the same dose of metformin throughout the study

          -  Age in the range of 18-85 years inclusive.

          -  HbA1c in the range of 6.5 - 8.0% (inclusive) at visit 1

          -  Agreement to maintain prior diet and exercise habits during the full course of the
             study

          -  Ability to comply with all study requirements and signed informed consent to
             participate in the study.

        Exclusion Criteria:

          -  Pregnant or lactating female

        A history of:

          -  type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of
             diabetes, e.g. Cushing's syndrome and acromegaly.

          -  acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state
             (coma) within the past 6 months.

        Any of the following significant laboratory abnormalities:

          -  ALT, AST greater than 2 times the upper limit of the normal range at visit 1.

          -  Direct bilirubin greater than the upper limit of the normal range at visit 1.

          -  Serum creatinine levels equal to or greater than 1.5 mg/dL (132 umol/L) males, equal
             to or greater than 1.4 mg/dL (123 umol/L) females, or a history of abnormal creatinine
             clearance at visit 1.

          -  Clinically significant TSH values outside of normal range at visit 1.

          -  Clinically significant laboratory abnormalities, confirmed by repeat measurement,
             other than hyperglycemia, hyperinsulinemia, and glycosuria at visit 1 Treatment with
             any oral anti-diabetic other than metformin within 3 months prior to visit 1

        Other protocol-defined inclusion/exclusion criteria may apply